Home » Stocks » ICLR

ICON plc (ICLR)

Stock Price: $199.33 USD 0.22 (0.11%)
Updated December 3, 4:00 PM EST - Market closed

ICLR Stock Price Chart

Key Info

Market Cap 10.69B
Revenue (ttm) 2.81B
Net Income (ttm) 373.99M
Shares Out 53.86M
EPS (ttm) 6.02
PE Ratio 33.14
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $199.33
Previous Close $199.11
Change ($) 0.22
Change (%) 0.11%
Day's Open 197.71
Day's Range 196.72 - 201.12
Day's Volume 365,243
52-Week Range 115.95 - 214.08

ICLR Stock News

Business Wire - 1 month ago

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference

Seeking Alpha - 1 month ago

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 month ago

Icon PLC (ICLR) delivered earnings and revenue surprises of 10.97% and 5.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 month ago

Shares of Icon (NASDAQ:ICLR) moved lower by 0.6% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 1.15% year over year to $1.72, wh...

Business Wire - 1 month ago

DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical ...

Business Wire - 1 month ago

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device in...

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device in...

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industrie...

Seeking Alpha - 4 months ago

ICON's (ICLR) CEO Steven Cutler on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Icon PLC (ICLR) delivered earnings and revenue surprises of 9.09% and 4.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of Icon (NASDAQ:ICLR) were unchanged after the company reported Q2 results.

Zacks Investment Research - 4 months ago

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 6 months ago

Wayfair stock benefited from the novel coronavirus and is up big year to date. It’s time to consider other stocks.

Other stocks mentioned: STRA, WDAY
Seeking Alpha - 7 months ago

ICON Public Limited Company (ICLR) CEO Dr. Steven Cutler on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Icon PLC (ICLR) delivered earnings and revenue surprises of -1.16% and 0.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 8 months ago

This week, we’re highlighting three stocks to buy that have been dragged down by the current market turmoil.

Other stocks mentioned: HD, TJX
Forbes - 8 months ago

These stocks are for great companies whose valuations are a little high. As valuations decline, investors should scoop up these quality businesses.

Other stocks mentioned: HD, TJX
Seeking Alpha - 9 months ago

ICON PLC (ICLR) CEO Steven Cutler on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.00% and -1.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

Other stocks mentioned: CDNS, CRL, TTC
Zacks Investment Research - 10 months ago

Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Seeking Alpha - 1 year ago

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

ERFSF vs. ICLR: Which Stock Is the Better Value Option?

Seeking Alpha - 1 year ago

Iconix Brand Group, Inc. (ICON) CEO Bob Galvin on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

ERFSF vs. ICLR: Which Stock Is the Better Value Option?

Seeking Alpha - 1 year ago

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.60% and 0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

ICON Public Limited Company (ICLR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 1 year ago

Icon is a top player in the CRO industry.

Seeking Alpha - 1 year ago

ICON plc (ICLR) CEO Steve Cutler on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Icon PLC (ICLR) delivered earnings and revenue surprises of 1.88% and 0.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

ICLR vs. HQY: Which Stock Is the Better Value Option?

Other stocks mentioned: HQY

About ICLR

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, stud... [Read more...]

Industry
Diagnostics & Research
IPO Date
May 15, 1998
CEO
Stephen Cutler
Employees
15,250
Stock Exchange
NASDAQ
Ticker Symbol
ICLR
Full Company Profile

Financial Performance

In 2019, ICON plc's revenue was $2.81 billion, an increase of 8.09% compared to the previous year's $2.60 billion. Earnings were $373.99 million, an increase of 15.91%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ICON plc is 205.14, which is an increase of 2.91% from the latest price.

Price Target
$205.14
(2.91% upside)